Iemoli E, Ortolani V G R, Preziosi D, Caron L, Giardina C, Carlevatti V, Giovine N
Allergy and Clinical Immunology Unit, ASST FBF-Sacco, Milan, Italy.
Department of Internal Medicine, Allergy Unit, ASST Valtellina e Alto Lario, Sondrio, Italy.
Eur Ann Allergy Clin Immunol. 2022 Sep;54(5):240-241. doi: 10.23822/EurAnnACI.1764-1489.236. Epub 2021 Nov 5.
Since December 2020, in various countries of the world, many cases of severe allergic reactions after administration of PfizerBioNTech COVID-19 vaccine, were reported. A great concern has arisen among the doctors who administer the vaccine and the allergic patients who undergo vaccinations. In Italy guidelines were published in order to stratify the risk in the allergic population. In mRNA vaccines, the component currently suspected of causing allergic reactions is the polyethylene glycol excipient (PEG or macrogol). In patients who have shown an immediate allergic reaction to vaccine and who are negative to skin tests for PEG, desensitization with the same vaccine is proposed. In this paper we describe two cases of asthma after the first COVID vaccine administration in which desensitization has failed.
自2020年12月以来，世界各国报告了多例接种辉瑞生物科技公司新冠疫苗后出现严重过敏反应的病例。这引起了接种疫苗的医生和接受疫苗接种的过敏患者的极大关注。在意大利，已发布指南以对过敏人群的风险进行分层。在mRNA疫苗中，目前怀疑导致过敏反应的成分是聚乙二醇辅料（PEG或聚乙二醇）。对于对疫苗出现即刻过敏反应且PEG皮肤试验呈阴性的患者，建议使用同一疫苗进行脱敏治疗。在本文中，我们描述了两例首次接种新冠疫苗后发生哮喘且脱敏治疗失败的病例。
